These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9027768)

  • 41. [Pleiotropic effects of new generation calcium channel blockers on cardiovascular protections].
    Ogimoto A; Higaki J
    Clin Calcium; 2013 Apr; 23(4):569-74. PubMed ID: 23545747
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Calcium channel blockers in the prevention of end stage renal disease: a review.
    Derwa A; Peeters P; Vanholder R
    Acta Clin Belg; 2004; 59(1):44-56. PubMed ID: 15065696
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Calcium antagonists and the kidney.
    Loutzenhiser RD; Epstein M
    Am J Hypertens; 1989 Jun; 2(6 Pt 2):154S-161S. PubMed ID: 2665786
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Calcium antagonists. History and perspective.
    Triggle DJ
    Stroke; 1990 Dec; 21(12 Suppl):IV49-58. PubMed ID: 2175461
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antagonists of neuronal calcium channels: structure, function, and therapeutic implications.
    Miljanich GP; Ramachandran J
    Annu Rev Pharmacol Toxicol; 1995; 35():707-34. PubMed ID: 7598513
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ligand action on sodium, potassium, and calcium channels: role of permeant ions.
    Zhorov BS; Tikhonov DB
    Trends Pharmacol Sci; 2013 Mar; 34(3):154-61. PubMed ID: 23375737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The IVS6 segment of the L-type calcium channel is critical for the action of dihydropyridines and phenylalkylamines.
    Schuster A; Lacinová L; Klugbauer N; Ito H; Birnbaumer L; Hofmann F
    EMBO J; 1996 May; 15(10):2365-70. PubMed ID: 8665843
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Calcium antagonists: current and future applications based on new evidence. Classification of calcium channel blockers].
    Takahara A
    Clin Calcium; 2010 Jan; 20(1):24-30. PubMed ID: 20048430
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of calcium channels that control neurosecretion.
    Dunlap K; Luebke JI; Turner TJ
    Science; 1994 Nov; 266(5186):828-31. PubMed ID: 7973643
    [No Abstract]   [Full Text] [Related]  

  • 50. Calcium channels blockers and progression of kidney disease.
    Ziakka S; Kaperonis N; Ferentinou E; Karakasis F; Ntatsis G; Kourvelou C; Papagalanis N
    Ren Fail; 2007; 29(8):1003-12. PubMed ID: 18067048
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modification of the renal hemodynamic response to vasoconstrictors by calcium antagonists.
    Loutzenhiser R; Epstein M
    Am J Nephrol; 1987; 7 Suppl 1():7-16. PubMed ID: 3442293
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dihydropyridine calcium antagonists and agonists in the isolated perfused Dahl rat kidney.
    Steele TH; Challoner-Hue L
    J Cardiovasc Pharmacol; 1987; 9 Suppl 1():S44-8. PubMed ID: 2441184
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design, synthesis, and biological testing of thiosalicylamides as a novel class of calcium channel blockers.
    Mehanna AS; Kim JY
    Bioorg Med Chem; 2005 Jul; 13(13):4323-31. PubMed ID: 15927838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. P2 receptor-mediated afferent arteriolar vasoconstriction during calcium blockade.
    Inscho EW; Cook AK
    Am J Physiol Renal Physiol; 2002 Feb; 282(2):F245-55. PubMed ID: 11788438
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The elements of commonality in calcium channel blockers and M-cholinolytics].
    Degtiar' VE; Poda GI; Skryma RN; Luĭk AI
    Dokl Akad Nauk SSSR; 1991; 318(1):221-3. PubMed ID: 1654245
    [No Abstract]   [Full Text] [Related]  

  • 56. [Pharmacological basis of Ca2+ channels and Ca2+ channel antagonists].
    Adachi-Akahane S
    Clin Calcium; 2005 Oct; 15(10):1589-97. PubMed ID: 16199903
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preservation of renal function: the spectrum of effects by calcium-channel blockers.
    Tarif N; Bakris GL
    Nephrol Dial Transplant; 1997 Nov; 12(11):2244-50. PubMed ID: 9394306
    [TBL] [Abstract][Full Text] [Related]  

  • 58. N-type calcium channel blockers from a marine bacterium, Cytophaga sp. SANK 71996.
    Morishita T; Sato A; Hisamoto M; Oda T; Matsuda K; Ishii A; Kodama K
    J Antibiot (Tokyo); 1997 Jun; 50(6):457-68. PubMed ID: 9268000
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The calcium antagonist drugs.
    Nayler WG
    Med J Aust; 1988 Dec 5-19; 149(11-12):682-6. PubMed ID: 2849033
    [No Abstract]   [Full Text] [Related]  

  • 60. Effects of calcium antagonists on renal function.
    Bauer JH; Reams GP
    Ann N Y Acad Sci; 1988; 522():785-92. PubMed ID: 3288069
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.